Ivd Infectious Disease Market Share, Size and Analysis to 2022

Submitted by: Submitted by

Views: 10

Words: 935

Pages: 4

Category: Business and Industry

Date Submitted: 03/28/2016 01:48 AM

Report This Essay

Global IVD infectious disease market is expected to reach 25.9 billion by 2022 according to a new report by Grand View Research Inc. Introduction of technologically advanced diagnostic devices along with associated benefits such as rapid result availability, improved accuracy, ease of usage, and cost-effectiveness is expected to serve this market as high-impact rendering drivers over the forecast period. For instance, Abbott Molecular has introduced a new range of real-time assays for HBV and HCV infections on its m200 platform.

Rising level of epidemics of communicable diseases such as H1N1 and Ebola virus is of growing concern in low-income countries. These diseases are reported to play a significant role in causing mortality in developing regions.

Browse Detail Report With TOC @ http://www.hexareports.com/report/ivd-infectious-disease-market/details

Low level of hygiene, less awareness levels, and social taboo for early testing are some of the drivers leading to increasing share of target population in low-income countries. According to the WHO, number of cases has increased by around 1 million each year with over 357 million people already suffering from one of the four types of STI. It is also estimated that over 290 million women are having HPV infection and over 25% of them are unaware of the infection.

Further key findings from the study suggest:

Reagents were one of the significant share holders of the IVD infectious disease market with the market size over USD 8,900 million. Wide range of available kits and extensive use of chemical reagents are estimated to be key factors for large market share.However, instruments owing to their speed, sensitivity, and ability to diagnose multiple samples in a single run will witness significant growth rate over the decade.Immunochemistry is one of the most conventional methods for infectious disease testing. ELISA is one of the leading technologies with market share of over 33.0%. Cost-effectiveness, large...